Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
6.53
-0.12 (-1.80%)
At close: Jul 2, 2026, 4:00 PM EDT
6.59
+0.06 (0.92%)
After-hours: Jul 2, 2026, 7:27 PM EDT
Taysha Gene Therapies Market Cap
Taysha Gene Therapies has a market cap or net worth of $2.09 billion as of July 2, 2026. Its market cap has increased by 213.19% in one year.
Market Cap
2.09B
Enterprise Value
1.88B
1-Year Change
213.19%
Ranking
Category
Stock Price
$6.53
Market Cap Chart
Since the IPO on September 24, 2020, Taysha Gene Therapies's market cap has increased from $690.43M to $2.09B, an increase of 202.52%. That is a compound annual growth rate of 21.14%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jul 2, 2026 | 2.09B | 38.64% |
| Dec 31, 2025 | 1.51B | 324.92% |
| Dec 31, 2024 | 354.55M | 7.14% |
| Dec 29, 2023 | 330.92M | 134.50% |
| Dec 30, 2022 | 141.12M | -68.52% |
| Dec 31, 2021 | 448.22M | -55.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Sep 24, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Agios Pharmaceuticals | 2.21B |
| Nektar Therapeutics | 2.18B |
| Kardigan | 2.15B |
| Zai Lab | 2.15B |
| Generate Biomedicines | 2.12B |
| Harmony Biosciences Holdings | 2.08B |
| Ocular Therapeutix | 2.07B |
| Viridian Therapeutics | 2.04B |